Literature DB >> 18954310

Combined penetrating keratoplasty and keratolimbal allograft transplantation in comparison with corneoscleral transplantation in the treatment of severe eye burns.

Weiyun Shi1, Hua Gao, Ting Wang, Lixin Xie.   

Abstract

PURPOSE: The aim of this study is to compare the therapeutic outcomes between penetrating keratoplasty (PK) combined with keratolimbal allograft (KLAL) transplantation and corneoscleral transplantation in patients with severe corneal burns.
METHODS: Thirty-eight patients (39 eyes) diagnosed severe corneal burns in stable status with vascularization and corneal opacity were included. We performed combined PK with KLAL transplantation in 23 eyes (group A) and corneoscleral transplantation in 16 eyes (group B). The main outcome measures were postoperative complications and long-term visual acuity and rejection.
RESULTS: The incidence of postoperative complications (corneal epithelium defect, hyphaema and hypotony) in group A were obviously less than those in group B. Fifteen eyes (65%) in group A and four eyes (25%) in group B had best-corrected visual acuity of >0.05 at 24 months (P = 0.022). Limbal stem cell rejection occurred in eleven grafts (48%) in group A and eight grafts (50%) in group B (P = 1.000). Nine grafts (39%) in group A and 12 grafts (54%) in group B had endothelial rejection (P = 0.049).
CONCLUSIONS: PK combined with KLAL transplantation may reduce the risk of postoperative complications. Long-term prognosis appears better than corneoscleral transplantation in the treatment of severe eye burns.

Entities:  

Mesh:

Year:  2008        PMID: 18954310     DOI: 10.1111/j.1442-9071.2008.01802.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  8 in total

1.  Partial lamellar keratoplasty for peripheral corneal disease using a graft from the glycerin-preserved corneoscleral rim.

Authors:  Hua Gao; Xiuxian Wang; Jose J Echegaray; Suxia Li; Ting Wang; Weiyun Shi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-06       Impact factor: 3.117

Review 2.  The application of human amniotic membrane in the surgical management of limbal stem cell deficiency.

Authors:  Qihua Le; Sophie X Deng
Journal:  Ocul Surf       Date:  2019-01-08       Impact factor: 5.033

3.  Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury.

Authors:  Joo Youn Oh; Gavin W Roddy; Hosoon Choi; Ryang Hwa Lee; Joni H Ylöstalo; Robert H Rosa; Darwin J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

4.  Diagnostic criteria for limbal stem cell deficiency before surgical intervention-A systematic literature review and analysis.

Authors:  Qihua Le; Tulika Chauhan; Sophie X Deng
Journal:  Surv Ophthalmol       Date:  2019-07-02       Impact factor: 6.048

5.  Ophthalmic transplantology: anterior segment of the eye - part I.

Authors:  Małgorzata Nita; Barbara Strzałka-Mrozik; Andrzej Grzybowski; Wanda Romaniuk; Urszula Mazurek
Journal:  Med Sci Monit       Date:  2012-05

6.  Total Penetrating Keratoplasty: Indications, Therapeutic Approach, and Long-Term Follow-Up.

Authors:  Katarzyna Krysik; Ewa Wroblewska-Czajka; Anita Lyssek-Boron; Edward A Wylegala; Dariusz Dobrowolski
Journal:  J Ophthalmol       Date:  2018-04-19       Impact factor: 1.909

7.  Long-Term Outcomes of Allogeneic Ocular Surface Reconstruction: Keratolimbal Allograft (KLAL) Followed by Penetrating Keratoplasty (PK).

Authors:  Katarzyna Krysik; Dariusz Dobrowolski; Dorota Tarnawska; Edward Wylegala; Anita Lyssek-Boroń
Journal:  J Ophthalmol       Date:  2020-04-14       Impact factor: 1.909

8.  Cell jamming, stratification and p63 expression in cultivated human corneal epithelial cell sheets.

Authors:  Koichi Baba; Kei Sasaki; Mio Morita; Tomoyo Tanaka; Yosuke Teranishi; Takahiro Ogasawara; Yoshinori Oie; Izumi Kusumi; Masukazu Inoie; Ken-Ichiro Hata; Andrew J Quantock; Masahiro Kino-Oka; Kohji Nishida
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.